Enlivex Ltd.

Enlivex Ltd. is a clinical-stage biotechnology company focused on macrophage reprogramming immunotherapy and inflammatory disease treatment. Its lead program, Allocetra, is designed to restore immune balance by reprogramming macrophages, with development efforts centered on conditions such as sepsis and osteoarthritis. The company’s current pipeline includes cell-based therapies for immune-related disorders and degenerative joint disease, reflecting its emphasis on novel approaches to immune modulation. Enlivex Ltd. operates from Ness Ziona, Israel, and serves the healthcare and biopharmaceutical markets through research, clinical development, and therapeutic innovation. The company’s role in the market is to advance experimental treatments that address unmet medical needs in inflammation-driven and immune dysregulation conditions.

Sector

Healthcare

Industry

Biotechnology

Employees

34

Headquarters

Ness Ziona, Israel

Website

www.enlivex.com